



## **Evogene to Present at the 26<sup>th</sup> Asian-Pacific Weed Science Society Conference**

***Boaz Inbal, R&D Director of Ag-Chemical division to present biology-driven computational chemistry discovery and optimization technology; and to describe Evogene's internal herbicide pipeline***

**Rehovot, Israel – August 22, 2017** - Evogene Ltd., (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity, announced today that the R&D director of its Ag-Chemicals activity area, Dr. Boaz Inbal, will present the company's biology-driven computational chemistry platform, including proprietary Artificial Intelligence predictive models, and novel product pipeline.

Dr. Inbal will be presenting at the Asian Pacific Weed Science Society Conference taking place September the 19<sup>th</sup>-22<sup>nd</sup>, 2017 in Kyoto, Japan. Dr. Inbal's presentation is scheduled for September 20<sup>th</sup> (Wed) at 14:30.

In his presentation, Dr. Inbal will describe Evogene's unique approach for biology-driven discovery and optimization of novel pesticides, addressing market challenges of increasing resistance and product safety. Evogene's computational platform is utilized in the collaboration with BASF, as well as in internal programs and other collaborations.

South East Asian markets are important Agriculture growth markets, as they consist of more than a third of the world's population. Evogene's unique approach complements the growing need for Ag-Innovation in these markets.

**-XXX**

### ***About Evogene Ltd.:***

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit [www.evogene.com](http://www.evogene.com) or contact the Company at [info@evogene.com](mailto:info@evogene.com).

### ***Forward Looking Statements:***

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking

statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

**Contact:**

Nir Zalik  
IR/PR Manager  
E: [IR@evogene.com](mailto:IR@evogene.com)  
T: (+972)-8-931-1963